Vermillion's Q4 Revenues Increase 152 Percent on OVA1 Sales | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Paced by accelerating sales of its OVA1 test, Vermillion today reported revenues in the fourth quarter rose 152 percent year over year.

For the period ended Dec. 31, 2011, total revenues were $868,000, up from $345,000 a year ago as product revenues, comprised of sales of the company's OVA1 ovarian cancer test, increased to $755,000 from $149,000 a year ago. Testing volume increased 40 percent year over year to 4,118, the firm said.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: genetic target for urothelial bladder cancer treatment, and more.

At the Conversation, the University of Oxford's Michael Macklay writes that learning genetic risk of disease is a personal decision.

Two dozen scientific organizations have endorsed the March for Science, according to ScienceInsider.

Researchers in Japan describe a chimpanzee with a chromosomal abnormality similar to human Down syndrome, Mashable reports.